Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | SK-MES-1 is a human lung cancer cell line established in 1975 by Jørgen Fogh and colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC). The cell line was derived from the metastatic pleural effusion of a 65-year-old Caucasian male patient diagnosed with pulmonary squamous cell carcinoma (epidermoid carcinoma). SK-MES-1 cells exhibit a polygonal shape and epithelial morphology, growing as a robust adherent monolayer. In the fields of translational thoracic oncology and cancer pharmacology, SK-MES-1 is a globally recognized cornerstone model for the in vitro study of lung squamous cell carcinoma (LSCC). It serves as a vital platform for investigating receptor tyrosine kinase signaling (particularly FGFR and EGFR family networks), screening targeted therapies, evaluating novel chemotherapeutic agents, and elucidating mechanisms of drug resistance in non-small cell lung cancer (NSCLC). |
| Tissue | Lung; derived from metastatic site (Pleural Effusion) |
| Cell Type | Epithelial cell |
| Population / Ancestry | Caucasian |
| Disease | Lung Squamous Cell Carcinoma (Epidermoid Carcinoma) / Non-Small Cell Lung Cancer (NSCLC) |
| Morphology | Epithelial-like |
| Gender | Male |
| Age | 65 years |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Biosafety classification matches standard international parameters for non-infectious human tumor cells) |
| Applications | 1. A "gold standard" in vitro model for studying receptor tyrosine kinase signaling networks (specifically FGFR1 amplification/activation and the downstream MAPK pathway in lung squamous cell carcinoma); 2. Preclinical high-throughput screening of novel small-molecule chemotherapeutics, targeted kinase inhibitors (such as pan-FGFR and EGFR inhibitors), and radiosensitizers; 3. Elucidation of multidrug resistance (MDR), drug efflux pump activity, and mechanisms of apoptosis evasion in thoracic malignancies; 4. Investigation of dynamic changes in epithelial marker expression, squamous differentiation, and cell-extracellular matrix adhesion; 5. Establishment of cell line-derived subcutaneous or orthotopic xenograft models in immunodeficient mice for in vivo efficacy evaluation. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes; forms progressively growing epidermoid carcinomas when inoculated subcutaneously into athymic nude rodents. |
| Transformant | None; immortalized spontaneously from advanced metastatic clinical tumor fluid. |
| Karyotype | Human hyperdiploid/hypotriploid karyotype with complex structural chromosome variations typical of advanced squamous lung malignancies. |
| Growth Kinetics | Robust adherent expansion; typical population doubling time spans approximately 30 to 42 hours. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Completely discard the old complete culture medium from the culture vessel. 2. Gently wash the cell monolayer with sterile PBS (lacking Ca2+ and Mg2+) to remove residual serum containing active trypsin inhibitors. 3. Add 1.0 to 2.5 mL of 0.25% trypsin-0.53 mM (0.02%) EDTA solution, pre-warmed to the appropriate temperature, ensuring the cell layer is completely covered. 4. Incubate at 37°C for 3 to 7 minutes; monitor closely under an inverted microscope until the cells round up, loosen, and detach completely. 5. Add an equal volume of pre-warmed complete growth medium to immediately neutralize trypsin activity. 6. Gently pipette the suspension to disperse cell clumps, centrifuge at approximately 125 × g for 5 minutes, carefully discard the supernatant, gently resuspend the cell pellet in fresh complete growth medium, and distribute the cells into new culture vessels. |
| Thawing Protocol Note | SK-MES-1 cells are sensitive to pH fluctuations during early post-thaw recovery. Prior to introducing the thawed vial contents, place the culture vessel containing fresh complete growth medium into the 5% CO2 incubator for at least 15 minutes to allow the medium to equilibrate to its physiological pH range (7.0 to 7.6). |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | Split confluent cultures (80% density) at a standard ratio of 1:2 to 1:4. Maintain active growth by subculturing before the culture reaches complete 100% confluence. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 90% Complete culture growth medium + 10% DMSO (or 50% Basal medium + 40% FBS + 10% DMSO) |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RO01220 | Cas9 Stable Cell Line - SK-MES-1 | Inquiry |
| CSC-RR00714 | Luciferase Reporter Cell Line - SK-MES-1 | Inquiry |
| CSC-RO01650 | OVAL Stable Cell Line - SK-MES-1 | Inquiry |
| CSC-RO01903 | GFP/OVAL Stable Cell Line - SK-MES-1 | Inquiry |
| CSC-RO02156 | Luc/OVAL Stable Cell Line - SK-MES-1 | Inquiry |
| CSC-RO02409 | GFP/Luc/OVAL Stable Cell Line - SK-MES-1 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.